Both fentanyl and lignocaine safe for preventing perioperative adverse respiratory events among pediatric patients: Study

Written By :  Dr Monish Raut
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-12 02:00 GMT   |   Update On 2024-09-12 06:43 GMT

Coughing during extubation is experienced by over 40% of patients undergoing surgery under general anesthesia. Any persistent coughing or breath-holding that results in airway obstruction and desaturation is considered a respiratory adverse event. Recent randomized double-blind pilot study compared the effects of intravenous (IV) lignocaine and fentanyl on neuromuscular recovery time and respiratory complications in 42 pediatric patients aged 2-8 years undergoing general anesthesia with neuromuscular blockade.

Advertisement

The primary objective was to compare the time to achieve a train of four (TOF) ratio of 0.9 and the time to extubation between the lignocaine and fentanyl groups. The secondary objectives were to compare the incidence of respiratory complications such as coughing, bucking, and laryngospasm.

The results showed that the time from reversal to achieving a TOF ratio of 0.9 was similar between the lignocaine (6.79 ± 3.03 minutes) and fentanyl (6.79 ± 3.31 minutes) groups (p=0.99). The time to extubation was also similar in both groups (8.14 ± 3.31 vs 9.19 ± 2.89 minutes, p=0.28). The incidence of bucking was slightly higher in the fentanyl group (23.8%) compared to the lignocaine group (9.5%), but this difference was not statistically significant (p=0.41). One patient in each group experienced laryngospasm and emergence delirium, which were successfully managed.

Advertisement

Conclusion and Recommendations

The study concluded that a single dose of IV lignocaine administered just before reversal did not prolong neuromuscular recovery time compared to fentanyl, with a similar low incidence of respiratory complications in pediatric patients undergoing general anesthesia with neuromuscular blockade. The authors recommend the use of neuromuscular monitoring in all pediatric patients receiving neuromuscular blockers, if feasible, to guide dosing and prevent residual neuromuscular blockade.

Key Points

Here are the 6 key points from the research paper summary:

1. This was a randomized double-blind pilot study that compared the effects of intravenous (IV) lignocaine and fentanyl on neuromuscular recovery time and respiratory complications in 42 pediatric patients aged 2-8 years undergoing general anesthesia with neuromuscular blockade.

2. The primary objective was to compare the time to achieve a train of four (TOF) ratio of 0.9 and the time to extubation between the lignocaine and fentanyl groups. The secondary objectives were to compare the incidence of respiratory complications such as coughing, bucking, and laryngospasm.

3. The results showed that the time from reversal to achieving a TOF ratio of 0.9 and the time to extubation were similar between the lignocaine and fentanyl groups.

4. The incidence of bucking was slightly higher in the fentanyl group compared to the lignocaine group, but this difference was not statistically significant. One patient in each group experienced laryngospasm and emergence delirium, which were successfully managed.

5. The study concluded that a single dose of IV lignocaine administered just before reversal did not prolong neuromuscular recovery time compared to fentanyl, with a similar low incidence of respiratory complications.

6. The authors recommend the use of neuromuscular monitoring in all pediatric patients receiving neuromuscular blockers, if feasible, to guide dosing and prevent residual neuromuscular blockade.

Reference –

Dhar M, Sharma R, Payal YS, Gupta V, Rawat J, Sogal S. Effect of single‑dose intravenous lignocaine versus fentanyl on neuromuscular recovery time after general anesthesia in elective pediatric surgery: A randomized controlled pilot study. J Anaesthesiol Clin Pharmaco 2024. DOI: 10.4103/joacp.joacp_460_23

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News